A Post-market Clinical Study to Evaluate the Safety and Performance of the Carbon Fibre Reinforced Polyetheretherketone Metatarso-Phalangeal (MTP) Plate (CoLink® PCR MTP Plate) for the Treatment of Hallux Rigidus
Study Details
Study Description
Brief Summary
The clinical study involves the routine treatment of skeletally mature patients who have been diagnosed with hallux rigidus (stiffness of the first metatarso-phalangeal joint in the foot due to arthritis and degeneration of cartilage).
It follows standard practice surgery to treat this condition. This type of degenerative arthritis affects the joint of the big toe (hallux) which is attached to the foot. Taking part in this research will involve collecting data of the surgery to remove damaged cartilage and fix the two bones together with screws and a plate (called the CoLink® PCR MTP Plate).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Bone Fusion [6 months]
Successful radiographic union: where union is defined as 'evidence of bridging' between the metatarsal bone and proximal phalanx bone by an independent imaging company.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects aged 18 years of age or older (> 18 years) and are skeletally mature.
-
Subjects who require surgical treatment for hallux rigidus and have been evaluated as appropriate candidates for treatment with the CoLink® PCR MTP Plate by the Investigator.
-
Subjects who, in the opinion of the Investigator, are able to understand this clinical study, co-operate with the procedures and are willing to return to the hospital for all the required post-operative follow-ups.
-
Subjects who are able to give voluntary, written informed consent to participate in this clinical study and from whom consent has been obtained.
Exclusion Criteria:
-
Subjects who have previously undergone MTP fusion surgery or implant arthroplasty in the foot to be treated.
-
Subjects who require bi-lateral MTP fusion surgery.
-
Subjects with evidence of tumour and/or malignant disease with resultant life expectancy of less than two years.
-
Subjects with a known allergy to the material used in the instrumentation.
-
Subjects with evidence of an active infection and/or with any condition that would compromise their participation and follow-up in this clinical study.
-
Subjects who have any conditions outlined as contraindicated in the Instructions for Use.
-
Female subjects who are pregnant or lactating.
-
Subjects who are known drug or alcohol abusers, or with a baseline opioid use greater than 30 mg of morphine equivalent/day, or with psychological disorders that could affect follow-up care or treatment outcomes.
-
Subjects who are current smokers or have stopped smoking less than 6 months ago.
-
Subjects who are currently enrolled in a clinical study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Invibio Ltd
- In2Bones
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IN2B01